Global Myasthenia Gravis Treatment Market Report 2023 - Opportunities in Tailored Treatment Approaches, Biologics and Immunotherapies and Patient-Centric Care

News provided by

Dec 06, 2023, 12:30 ET

DUBLIN , Dec. 6, 2023 /PRNewswire/ -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.

The global market for myasthenia gravis treatments was valued at nearly $1.2 billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of 10.5%, reaching $2.2 billion in 2028. Growth in this market is fueled by a worldwide increase in elderly populations and an increased prevalence of myasthenia gravis.

Technological innovation is an important catalyst driving adaptation and use. In 2022, the generalized myasthenia gravis segment held the highest market share at about 85.1%, followed by ocular myasthenia gravis at 7.9% and transient neonatal myasthenia gravis at 7.0%.

The expansion of the Myasthenia Gravis market is propelled by the advancement of treatment strategies, encompassing innovative therapies and tailored approaches. The growing awareness within both medical practitioners and patients plays a pivotal role in enabling timely diagnosis and intervention. Additionally, the increasing prevalence of Myasthenia Gravis drives the demand for a more comprehensive array of treatment choices. Ongoing research endeavors and collaborative initiatives further contribute to an enhanced understanding of therapeutics, fostering innovation in the field.

This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.

The Report Includes

An overview and analysis of the global market for myasthenia gravis (MG) treatments
Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
Analysis of the market growth opportunities through Porter's Five Forces and PESTLE analyses, taking into consideration the prevailing micro
and macro environmental factors
An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
Discussion of the factors driving the market, industry trends and new developments
Analysis of relevant patents
Identification of the leaders in the field of MG
Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva

Market Dynamics

Market Drivers

Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine

Market Opportunities

Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration

Market Restraints

Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Summary and Highlights

Chapter 3: Market Overview

Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications
Surgery
Intravenous (IV) Therapy
Medications

Chapter 4: Market Dynamics

Chapter 5: Market Breakdown by Region

Chapter 6: Market Breakdown by Type

Market Overview
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Ocular Myasthenia Gravis

Chapter 7: Market Breakdown by Treatment Modality

Medications
Surgery
Intravenous Therapy

Chapter 8: Market Breakdown by Type of Product

Monoclonal Antibodies
Cholinesterase Inhibitors
Intravenous Immunoglobulins
Immunosuppressants
Corticosteroids

Chapter 9: ESG Development

Chapter 10: Emerging Technologies and Developments

Chapter 11: Competitive Intelligence

Chapter 12: Patent Analysis

Chapter 13: Pipeline Analysis

Chapter 14: M&A and Venture Funding Outlook

Chapter 15: Company Profiles

AbbVie
Amyasthenia Gravisen
Astellas Pharma
AstraZeneca
Bausch Health Companies
Bayer
Biogen
Bristol-Myers Squibb
CSL
Daiichi Sankyo Co. Ltd.
F. Hoffmann-La Roche AG
Gilead Sciences Inc.
GlaxoSmithKline PLC
Merck & Co. Inc.
Novartis
Pfizer Inc.
Sanofi
Servier Laboratories
Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ocmxm3

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets